Basilea Pharmaceutica AG announced earnings results for the half year ended June 30, 2021. For the half year, the company announced total revenue was CHF 54.198 million compared to CHF 69.328 million a year ago. Operating loss was CHF 15.355 million compared to operating Income of CHF 12.814 million a year ago. Net loss was CHF 19.891 million compared to net income of CHF 9.941 million a year ago. Basic loss per share from continuing operations was CHF 1.84 compared to basic earnings per share from continuing operations of CHF 0.92 a year ago. Diluted loss per share from continuing operations was CHF 1.84 compared to diluted earnings per share from continuing operations of CHF 0.91 a year ago.